CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company developing innovative technologies and products for medical aesthetics tissue regeneration and organ manufacturing. The company focuses on medical aesthetics and 3D bioprinting of tissues and organs leveraging its proprietary recombinant human collagen rhCollagen produced in genetically engineered tobacco plants. This rhCollagen is structurally and functionally identical to the type I collagen found in the human body providing a bioidentical scaffold for tissue repair and regeneration. By combining rhCollagen with advanced biomaterials expertise CollPlant aims to create a broad pipeline of products that address unmet needs in aesthetics and regenerative medicine.

CollPlant generates revenue primarily from the sale of its rhCollagen based products which include bioinks for 3D bioprinting, collagen solutions such as Collage, and medical devices like VergenixSTR. The company also earns milestone payments and royalties under collaboration agreements notably the agreement with AbbVie for dermal and soft tissue filler development which has already yielded $10 million and $2 million payments upon achievement of clinical milestones. Additionally, CollPlant supplies its recombinant human collagen to STEMCELL Technologies, which incorporates it into cell culture media kits used by research and academic institutes, generating recurring product sales. The firm further monetizes its technology through licensing arrangements and the sale of its commercial rhCollagen based kits such as Collink.3D in various formats to bioprinting users and industrial partners. Revenue is also derived from providing contract manufacturing services and supplying rhCollagen for partner led product commercialization, although the majority of income stems from product sales and milestone receipts.

CollPlant occupies a unique position in the regenerative medicine and aesthetics markets as the only company known to have a commercially viable plant based platform for mass producing human type I collagen. This capability differentiates it from competitors that rely on animal derived or cadaveric collagen such as Galderma, Merz Aesthetics, Sinclair, and AbbVie in the filler space, and Establishment Labs Holdings Inc. and Mentor Worldwide LLC in the breast implant market. In the bioink arena, CollPlant’s offerings compete with products from BICO (formerly Cellink), Allevi Inc. (now part of 3D systems), and Humabiologics, which also provide collagen based inks but lack the same level of homogeneity and immunogenicity profile. CollPlant’s rhCollagen provides superior biofunctionality, high batch to batch consistency, and a markedly reduced risk of immune response, enabling faster tissue integration, lower scarring, and improved mechanical properties in its products. These advantages are supported by preclinical and clinical data showing enhanced fibroblast proliferation, vascularization, and tissue regeneration compared with traditional collagen based alternatives.

CollPlant sells its products directly to business partners and collaborators, including AbbVie, STEMCELL Technologies, and Stratasys, which use the collagen in joint development programs and commercial kits. The company also supplies its rhCollagen to research institutions, academic laboratories, and biotechnology firms that incorporate the material into experimental cell culture media, tissue engineering scaffolds, and preclinical studies. Additionally, CollPlant’s commercial kits such as Collink.3D and VergenixSTR are sold to medical device manufacturers, clinics, and hospitals seeking advanced biomaterials for implantation or wound care applications. Overall, the customer base spans partners in the aesthetics, regenerative medicine, and 3D bioprinting sectors, as well as academic and industrial users of collagen based bioinks.